

# Lucie Biard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7496761/publications.pdf>

Version: 2024-02-01

58  
papers

1,506  
citations

361388

20  
h-index

345203

36  
g-index

59  
all docs

59  
docs citations

59  
times ranked

2492  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of TNF- $\alpha$ antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384.	1.9	26
2	DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses. <i>Biometrical Journal</i> , 2022, 64, 1486-1497.	1.0	1
3	Anti-Tumor Necrosis Factor $\alpha$ versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema. <i>Ophthalmology</i> , 2022, 129, 520-529.	5.2	32
4	Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals. <i>American Journal of Gastroenterology</i> , 2022, 117, 627-636.	0.4	9
5	Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients. <i>American Journal of Ophthalmology</i> , 2022, 238, 173-180.	3.3	13
6	Cerebrovascular Ischemic Events in Patients With Takayasu Arteritis. <i>Stroke</i> , 2022, 53, 1550-1557.	2.0	12
7	Association of COVID-19 Acute Respiratory Distress Syndrome With Symptoms of Posttraumatic Stress Disorder in Family Members After ICU Discharge. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1042.	7.4	49
8	PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 491-500.	10.7	20
9	Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome" by Quartuccio et al. <i>Joint Bone Spine</i> . 2020;87:191-193. <i>Joint Bone Spine</i> , 2021, 88, 105074.	1.6	5
10	A simulation study of approaches for handling disease progression in dose-finding clinical trials. <i>Journal of Biopharmaceutical Statistics</i> , 2021, 31, 156-167.	0.8	8
11	Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to <i>Pneumocystis pneumonia</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1191-1198.	2.9	7
12	Bayesian survival analysis for early detection of treatment effects in phase 3 clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100709.	1.1	5
13	Direct oral anticoagulant for venous thrombosis in Behçet's syndrome. <i>Autoimmunity Reviews</i> , 2021, 20, 102783.	5.8	7
14	Seamless phase I/II design for novel anticancer agents with competing disease progression. <i>Statistics in Medicine</i> , 2021, 40, 4568-4581.	1.6	5
15	Spectrum and Outcome of Noninfectious Aortitis. <i>Journal of Rheumatology</i> , 2021, 48, 1583-1588.	2.0	4
16	Non-C. difficile Clostridioides Bacteremia in Intensive Care Patients, France. <i>Emerging Infectious Diseases</i> , 2021, 27, 1840-1849.	4.3	5
17	Rituximab-associated Vasculitis Flare: Incidence, Predictors, and Outcome. <i>Journal of Rheumatology</i> , 2020, 47, 896-902.	2.0	21
18	Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2020, 15, e0240711.	2.5	54

#	ARTICLE	IF	CITATIONS
19	Dose-finding design and benchmark for a right censored endpoint. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 948-963.	0.8	6
20	Outcomes in 886 Critically Ill Patients After Near-Hanging Injury. <i>Chest</i> , 2020, 158, 2404-2413.	0.8	10
21	Cardiac sarcoidosis: A long term follow up study. <i>PLoS ONE</i> , 2020, 15, e0238391.	2.5	32
22	Correspondance on â€Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseasesâ€™. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-219566.	0.9	0
23	Neutrophilâ€™Platelet and Monocyteâ€™Platelet Aggregates in COVID-19 Patients. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1733-1735.	3.4	41
24	Cryoglobulinemia after the era of chronic hepatitis C infection. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 695-700.	3.4	23
25	Long-Term Outcome and Prognosis Factors of Isolated Aortitis. <i>Circulation</i> , 2020, 142, 92-94.	1.6	22
26	Infectious disease consultation for candidaemia. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 164-165.	9.1	2
27	Title is missing!. , 2020, 15, e0240711.		0
28	Title is missing!. , 2020, 15, e0240711.		0
29	Title is missing!. , 2020, 15, e0240711.		0
30	Title is missing!. , 2020, 15, e0240711.		0
31	Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients. <i>Journal of Autoimmunity</i> , 2019, 96, 35-39.	6.5	61
32	Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1665.	4.8	31
33	TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses. <i>Journal of Hepatology</i> , 2019, 71, 908-919.	3.7	23
34	Long-term health-related quality of life of critically ill patients with haematological malignancies: a prospective observational multicenter study. <i>Annals of Intensive Care</i> , 2019, 9, 2.	4.6	17
35	Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. <i>Leukemia and Lymphoma</i> , 2019, 60, 2802-2805.	1.3	10
36	Center Effects in Hospital Mortality of Critically Ill Patients With Hematologic Malignancies*. <i>Critical Care Medicine</i> , 2019, 47, 809-816.	0.9	12

#	ARTICLE	IF	CITATIONS
37	Intensive care unit admission in patients with T cell lymphomas: clinical features and outcome. <i>Annals of Hematology</i> , 2019, 98, 195-203.	1.8	5
38	Incidence, risk factors and outcome of multi-drug resistant <i>Acinetobacter baumannii</i> nosocomial infections during an outbreak in a burn unit. <i>International Journal of Infectious Diseases</i> , 2019, 79, 179-184.	3.3	36
39	Granulocyte colony-stimulating factor and respiratory status of critically ill neutropenic patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2019, 60, 1156-1163.	1.3	6
40	Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1 <sup>+</sup> Tim-3 <sup>+</sup> CD8 <sup>+</sup> T Cells. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	14
41	Acute kidney injury in critically ill patients with solid tumours. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1997-2005.	0.7	26
42	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. <i>Oncoimmunology</i> , 2017, 6, e1286437.	4.6	28
43	Gastrointestinal emergencies in critically ill cancer patients. <i>Journal of Critical Care</i> , 2017, 40, 69-75.	2.2	14
44	Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis. <i>JAMA Neurology</i> , 2017, 74, 1336.	9.0	76
45	Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis. <i>Circulation</i> , 2017, 136, 1114-1122.	1.6	161
46	Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. <i>Cancer Research</i> , 2017, 77, 1075-1082.	0.9	166
47	Severe infections in sarcoidosis. <i>Medicine (United States)</i> , 2017, 96, e8846.	1.0	46
48	Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. <i>Arthritis and Rheumatology</i> , 2016, 68, 1522-1530.	5.6	131
49	<sup>18</sup> F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen. <i>Journal of Nuclear Medicine</i> , 2016, 57, 536-543.	5.0	40
50	Interaction Between Center Effect and Strategy for Graft Vs. Host Disease Prophylaxis on Outcome of T-Cell Depleted and T-Cell Replete Haploidentical Transplants, an Analysis on Behalf of ALWP-EBMT. <i>Blood</i> , 2016, 128, 3488-3488.	1.4	0
51	Impact of the source of hematopoietic stem cell in unrelated transplants: Comparison between 10/10, 9/10 HLA matched donors and cord blood. <i>American Journal of Hematology</i> , 2015, 90, 897-903.	4.1	14
52	Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. <i>European Journal of Dermatology</i> , 2015, 25, 36-44.	0.6	35
53	Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 509-15.	0.8	18
54	Behçet's disease in budd-chiari syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 104.	2.7	57

#	ARTICLE	IF	CITATIONS
55	Single-center experience in French Temporary Authorization for Use (TAU) metastatic melanoma program with ipilimumab.. Journal of Clinical Oncology, 2014, 32, e20034-e20034.	1.6	1
56	Neutropenic Enterocolitis: Clinical Features and Outcomes. Blood, 2014, 124, 5984-5984.	1.4	0
57	Personal Decision-Making Criteria Related to Seasonal and Pandemic A(H1N1) Influenza-Vaccination Acceptance among French Healthcare Workers. PLoS ONE, 2012, 7, e38646.	2.5	17
58	Case-Only Designs in Pharmacoepidemiology: A Systematic Review. PLoS ONE, 2012, 7, e49444.	2.5	32